September 16, 2025
George Tidmarsh, head of the FDA Center for Drug Evaluation and Research, said the agency "would like to get away" from convening expert panels on individual drugs.
FDA YouTube

STAT+ | FDA leaders moving to abandon advisory committee reviews of specific new drugs

The agency “would like to get away” from assembling panels of experts to examine individual drugs, said a top official, George Tidmarsh

By Arthur Allen — KFF Health News


STAT+ | Hill staff gets briefed on implications of Trump’s drug pricing plan

Experts from right- and left-leaning think tanks join Congressional staff to discuss Trump's most-favored nation drug pricing plan.

By Daniel Payne


Opinion: The Trump admin’s cruel disbanding of the Pediatric Brain Tumor Consortium

Because of the disbanding of the PBTC, children with rare brain cancers may be denied new and promising treatments.

By Josie Glausiusz



Adobe

STAT+ | Inside the hospital ‘war rooms’ bracing for Medicaid cuts

Hospitals nationwide prepare for nearly $1T in Medicaid cuts, weighing service reductions, consolidation, and new tech as patient care hangs in the balance.

By Daniel Payne


More around STAT

In case you missed it


Check out more exclusive coverage with a STAT+ subscription
Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

Enjoying Cancer Briefing? Tell us about your experience
Continue reading the latest health & science news with the STAT app
Download on the App Store or get it on Google Play
STAT
STAT, 1 Exchange Place, Boston, MA
©2025, All Rights Reserved.